Stocks · News reference

Analysts Raise Price Targets for Eli Lilly Following Q3 Results

2026-10-30 18:02:12 UTC

Following strong third-quarter earnings, analysts from UBS and BMO increased their price targets for Eli Lilly.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.ai2026-10-31 13:01:35 UTC
Eli Lilly CEO Dave Ricks Engages in Public Exchange Regarding Pharmaceutical Innovation
Eli Lilly CEO Dave Ricks publicly responded to skepticism from venture investor Vinod Khosla regarding the potential for large pharmaceutical companies to drive major medical breakthroughs.
LLY
Benzinga2026-10-30 18:56:09 UTCBenzinga Newsdesk
Scotiabank Maintains Sector Outperform on Eli Lilly, Raises Price Target to $1605
LLY
Benzinga2026-10-30 18:01:43 UTCBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1596
LLY
Benzinga2026-10-30 17:45:18 UTCVandana Singh
Eli Lilly 'Deserves' Stock Upside: Analyst
Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.
LLY
Benzinga2026-10-30 16:47:14 UTCBenzinga Newsdesk
Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1500
LLY
Benzinga2026-10-30 15:48:18 UTCBenzinga Newsdesk
RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1600
LLY